Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a group leader at Inserm UMR1188 DéTROI laboratory. Lambert was awarded a PhD in Pathophysiology from the University of Paris in 1998. He specialized in lipidology, first as a post-doctoral fellow at the Molecular Disease Branch of the National Institutes of Health (Bethesda MD, USA) under the supervision of Dr. H Bryan Brewer Jr. and then as a senior research fellow at the Heart Research Institute (Sydney NSW, Australia) in the lipid research group led by Pr. Philip Barter. In recent years, Pr. Lambert has conducted seminal research projects on PCSK9, a protein that targets the LDL receptor for intracellular degradation, and as such, the target of novel cholesterol lowering therapies: the PCSK9 inhibitors. His current research interests are to elucidate the specific role of PCSK9 in insulin producing beta-cells and to understand the cellular pathways by which PCSK9 modulates the circulating levels of lipoprotein (a), a highly atherogenic lipoprotein species.